J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Posted ContentDOI
Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated Vaccinia
Won Jing Wang,P. Dai,Shuaitong Liu,N. Yang,Yuxiang Wang,R. A. Giese,Taha Merghoub,Jedd D. Wolchok,Liang Deng +8 more
TL;DR: In this paper, a replication-competent, oncolytic vaccinia virus (OV-GM) was inserted into the thymidine kinase locus of a mutant vaccinia E3L{Delta}83N, which lacks the Z-DNA-binding domain of vaccinia virulence factor E3.
A delicate interplay between adaptive and innate immunity caused by immunotherapy triggers tumor immunity and aseptic inflammation
Daniel Hirschhorn,J. Ricca,Billel Gasmi,O. DeHanau,L. M. Mangarin,Sadna Budhu,Y. Y. Li,C. Cortez,C. L. Liu,Roberta Zappasodi,Sean Houghton,A. Betof,M. Lacouture,T. Hollman,Jean Albrengues,Mikala Egeblad,Jedd D. Wolchok,Taha Merghoub +17 more
Journal ArticleDOI
Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
Jianda Yuan,Jun Zhou,Zhiwan Dong,Sapna Tandon,Deborah Kuk,Katherine S. Panageas,Philip C. Wong,Jedd D. Wolchok,Jedd D. Wolchok,F. Stephen Hodi +9 more
TL;DR: Serum V EGF may be a predictive biomarker to ipilimumab treatment, and prospective investigation warranted, and there was no correlation between the change of VEGF and clinical outcome.
Proceedings ArticleDOI
Abstract PR06: Overcoming intratumor T-cell exclusion by modulation of lactate metabolism to improve immune checkpoint therapies in aggressive breast cancer
Roberta Zappasodi,Arnab Ghosh,Inna Serganova,Ivan J. Cohen,Yasin Senbabaoglu,Masahiro Shindo,Mayuresh Mane,Avigdor Leftin,Ellen Ackerstaff,Jason A. Koutcher,Jedd D. Wolchok,Ronald G. Blasberg,Taha Merghoub +12 more
TL;DR: Patients harboring tumors with high expression of lactate dehydrogenase A (LDH-A) or the lactate transporters MCT-1/4 have a significantly higher risk to develop metastases, whereas those having tumors with increased expression of CD3 and CD8 transcripts experience a better prognosis.
Journal ArticleDOI
9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma
C. Robert,Luc Thomas,Claus Garbe,C. Lebbé,Jean-François Baurain,Alessandro Testori,Michele Maio,T. Chen,A. Hoos,Jedd D. Wolchok +9 more